Skip to main content

Table 3 Comparative analysis of clinicopathological characteristics based on the size of primary tumors

From: Adjuvant Radioactive iodine 131 ablation in papillary microcarcinoma of thyroid: Saudi Arabian experience

Variable

Tumor size ≤ 0.5 cm N (%)

Tumor size > 0.5 cm N (%)

P value

 Total patients

161/326 (49.4)

165/326 (50.6)

-

Age (years)

36.7 (8–71)

47.8 (8–76)

 

 ≤45 years

107 (66.5)

94 (56.9)

0.034

 ≥45 years

54 (33.5)

71 (43.1)

 

Gender

 Female

139 (86.4)

132 (80.0)

0.08

 Male

22 (13.6)

33 (20.0)

 

Mean size (cm)

0.38 (0.1–0.5)

0.68 (0.6–1.0)

<0.001

Histopathologic variants

 Classic

126 (78.2)

139 (84.3)

 

 Follicular

26 (16.2)

14 (8.5)

 

 Hurthle cell

4 (2.5)

4 (2.4)

0.023

 Tall cell

4 (2.5)

7 (4.3)

 

 Sclerosing

1 (0.6)

-

 

Multifocal

 Yes

36 (22.4)

89 (53.9)

 

 No

125 (77.6)

76 (46.1)

<0.001

ETE

 Yes

16 (9.9)

46 (27.9)

<0.001

 No

145 (90.1)

119 (72.1)

 

LVSI

 Yes

14 (8.7)

41 (24.9)

<0.001

 No

147 (91.3)

124 (75.1)

 

Surgical margins

 Positive

5 (3.1)

30 (18.2)

 

 Negative

156 (96.9)

135 (81.8)

<0.001

Background thyroid tissue

 Normal

60 (37.3)

38 (23.0)

 

 Multi-nodular goiter

48 (29.8)

58 (35.2)

 

 Lymphocytic thyroiditis/Hashimotos’ thyroiditis

53 (32.9)

69 (41.8)

0.05

Lymph node metastasis

 Yes

15 (9.3)

27 (16.4)

 

 No

146 (90.7)

138 (83.6)

<0.001

RAI ablation

 Yes

50 (31.1)

132 (67.3)

<0.001

 No

111 (68.9)

22 (13.3)

 

Recurrences

 Locoregional

4 (2.5)

9 (5.5)

 

 Thyroid bed

1/4

2/9

 

 Lymph nodes

3/4

7/9

<0.001

 Distant

2 (1.3)

8 (4.9)

 

 Lungs

2

7/8

 

 Bone

-

1/8

 
  1. I-131 radioactive iodine 131, N number, ETE extra-thyroidal extension, LVSI lymphovascular space invasion, RAI radioactive iodine